ENTITY
Innovent Biologics Inc

Innovent Biologics Inc (1801 HK)

350
Analysis
Health CareChina
Innovent Biologics, Inc. operates as a biopharmaceutical company. The Company develops, manufactures, and distributes monoclonal antibody drug candidates for the treatment of oncology, ophthalmology, autoimmune, cardiovascular, and other diseases. Innovent Biologics serves customers in China.
more
Refresh
19 Jun 2024 07:47Broker

Innovent Biologics (1801 HK) - Promising PoC Results of the Potential FIC Asset

IBI363 is a potential FIC PD-1/IL-2 bsAb with a differentiated α-biased IL-2 arm, distinct from other IL-2 mAbs that eliminate the receptor α.

Logo
91 Views
Share
22 Apr 2024 05:08

Innovent Biologics(1801 HK)– More than Just a GLP-1 Play

Mazdutide's strong results will position it well against the competition, and the valuation gap will narrow. The oncology portfolio will continue...

Logo
315 Views
Share
16 Apr 2024 08:55

2024 High Conviction Update: Innovent (1801.HK) - Breakeven Is Still on Track Despite Soaring Costs

Loose cost control led to an expansion of losses in 23H2, but the goal of breakeven in 2025 is still within the plan, which could be achieved...

Logo
435 Views
Share
06 Mar 2024 08:55

2024 High Conviction Update: Innovent (1801.HK) - Recent Promising Business Updates and 2024 Outlook

Innovent's product revenue growth will remain strong in 2024.The main flashpoint for performance is after the approval of mazdutide in...

Logo
404 Views
Share
23 Mar 2024 05:37Broker

Innovent Biologics (1801 HK) - More than Obesity

Strong product sales in FY23. In FY23, Innovent recorded total revenue of RMB6.21bn, including RMB5.73bn product sales revenue (+38.4% YoY), in...

Logo
371 Views
Share
x